Singular Genomics Systems
Accelerating genomics for the advancement of science and medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 -24.8x EV/EBITDA | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 281 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (11780 %) | (2971 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (11880 %) | (3257 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 6039 % | 1641 % |
Source: Company filings or news article
Related Content
Singular Genomics, founded in 2016 by Drew, is a biotechnology company based in San Diego, California. The company focuses on advancing genomics, which is the study of an organism's complete set of DNA, including all of its genes. Singular Genomics aims to accelerate scientific and medical research by providing innovative tools and technologies for genomic sequencing.
The company serves a variety of clients, including academic researchers, pharmaceutical companies, and clinical laboratories. These clients use Singular Genomics' products to conduct multiomic research, which involves studying various types of biological data, such as DNA, RNA, and proteins, to understand complex biological systems and diseases.
Singular Genomics operates in the genomics market, which is a rapidly growing sector within the broader biotechnology industry. The company's flagship product is the G4 sequencing platform, an ultra-high throughput, high-resolution spatial sequencing system. This platform allows researchers to process multiple samples simultaneously, making it faster and more efficient to conduct large-scale genomic studies.
The business model of Singular Genomics revolves around selling its sequencing platforms and related consumables, such as flow cells, which are essential components used in the sequencing process. The company generates revenue by selling these products to its clients, who rely on them for their research and clinical applications.
In summary, Singular Genomics is a forward-thinking biotech company dedicated to advancing genomics through innovative sequencing technologies. By providing high-performance tools for genomic research, the company supports the scientific and medical communities in their efforts to understand and treat complex diseases.
Keywords: genomics, sequencing, biotechnology, multiomic research, DNA, RNA, proteins, G4 platform, academic researchers, pharmaceutical companies.